BeiGene / BeOne Medicines Patent-Cliff Exposure & CMS Drug Spending Portfolio

BeiGene / BeOne Medicines (San Mateo, CA): 3 reconciled FDA prescription therapies, $1.77B 2024 CMS Part D & Medicaid spend, and $39,720 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterSan Mateo, CA
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2039-01-01
2024 CMS Total Public Spend$1.77B
2024 Medicare Part D Spend$1.72B
2024 Medicaid Spend$47.1M
California HCAI SB 17 FilingsSpecialty launch notice ($39,720 intro WAC)